The Predictive Value of Longitudinal Monitoring of Mutated EGFR in Plasma of Advanced NSCLC Patients on First-Line EGFR-TKIs

被引：0
|
作者：
Szpechcinski, A. [1 ]
Bryl, M. [2 ]
Wojda, E. [1 ]
Czyzewicz, G. [3 ]
Swiniuch, D. [4 ]
Szwiec, M. [5 ]
Ramlau, R. [4 ]
Sliwinski, P. [1 ]
Barinow-Wojewodzki, A. [2 ]
Chorostowska-Wynimko, J. [1 ]
机构：
[1] Inst TB & Lung Dis, Warsaw, Poland
[2] EJ Zeyland Wielkopolska Ctr Pulmonol & Thorac Sur, Poznan, Poland
[3] John Paul II Specialist Hosp, Krakow, Poland
[4] Med Univ Poznan, Poznan, Poland
[5] Univ Hosp Zielona Gora, Zielona Gora, Poland
来源：
JOURNAL OF THORACIC ONCOLOGY | 2022年 / 17卷 / 09期
关键词：
non-small cell lung cancer; EGFR mutations; liquid biopsy;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP08.02-07
引用
收藏
页码：S434 / S435
页数：2
相关论文
共 50 条
  • [41] An updated network meta-analysis of EGFR-TKIs and combination therapy in the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer
    Qi, Yuexiao
    Xia, Xiaojun
    Shao, Lihua
    Guo, Liyun
    Dong, Yumei
    Tian, Jinhui
    Xu, Lijun
    Niu, Ruijun
    Wei, Shihong
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [42] Expert consensus on the use of third-generation EGFR-TKIs in EGFR-mutated advanced non-small cell lung cancer with various T790M mutations post-resistance to first-/second-generation EGFR-TKIs
    Ma, Jietao
    Huang, Letian
    Han, Chengbo
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
  • [43] Efficacy and Safety of Third-Generation EGFR-TKIs Combined with Radiotherapy for Advanced NSCLC with Typical EGFR Mutations: A Retrospective Study
    Zhang, Wen-xuan
    Xue, Hui-chan
    Zhao, Ye
    Xu, Shuang-bing
    CURRENT MEDICAL SCIENCE, 2025, : 280 - 287
  • [44] Prognostic factors influencing overall survival in stage IV EGFR-mutant NSCLC patients treated with EGFR-TKIs
    Kuang, Linwu
    Zhang, Yuchen
    Wang, Hao
    Wang, Peng
    Li, Yangkai
    BMC PULMONARY MEDICINE, 2025, 25 (01):
  • [45] Estimation of cell-free circulating EGFR mutation concentration predicts outcomes in NSCLC patients treated with EGFR-TKIs
    Zhu, Yan-juan
    Zhang, Hai-bo
    Liu, Yi-hong
    Zhang, Fu-li
    Zhu, Ya-zhen
    Li, Yong
    Bai, Jian-ping
    Liu, Li-rong
    Qu, Yan-chun
    Qu, Xin
    Chen, Xian
    Li, Yan
    Zheng, Guang-juan
    ONCOTARGET, 2017, 8 (08) : 13195 - 13205
  • [46] Baseline Lymphocyte-Monocyte Ratio Is a Prognostic Marker in EGFR Mutant NSCLC Patients Receiving First Line EGFR TKIs
    Chen, Yu -Mu
    Lin, Meng-Chih
    Fang, Wen-Feng
    Lie, Chien-Hao
    Chang, Huang-Chih
    Wang, Chin-Chou
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S527 - S527
  • [47] Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02)
    Lee, Ji Yun
    Xu Qing
    Wei Xiumin
    Bai Yali
    Chi, Sangah
    Bak, So Hyeon
    Lee, Ho Yun
    Sun, Jong-Mu
    Lee, Se-Hoon
    Ahn, Jin Seok
    Cho, Eun Kyung
    Kim, Dong-Wan
    Kim, Hye Ryun
    Min, Young Joo
    Jung, Sin-Ho
    Park, Keunchil
    Mao Mao
    Ahn, Myung-Ju
    ONCOTARGET, 2016, 7 (06) : 6984 - 6993
  • [48] Clinical efficacy of first-generation EGFR-TKIs in patients with advanced non-small-cell lung cancer harboring EGFR exon 20 mutations
    Chen, Dan
    Song, Zhengbo
    Cheng, Guoping
    ONCOTARGETS AND THERAPY, 2016, 9 : 4181 - 4186
  • [49] Efficacy of EGFR-TKIs with or without upfront brain radiotherapy for EGFR-mutant NSCLC patients with central nervous system metastases
    Saida, Yu
    Watanabe, Satoshi
    Abe, Tetsuya
    Shoji, Satoshi
    Nozaki, Koichiro
    Ichikawa, Kosuke
    Kondo, Rie
    Koyama, Kenichi
    Miura, Satoru
    Tanaka, Hiroshi
    Okajima, Masaaki
    Terada, Masaki
    Ishide, Takashi
    Tsukada, Hiroki
    Makino, Masato
    Iwashima, Akira
    Sato, Kazuhiro
    Matsumoto, Naoya
    Yoshizawa, Hirohisa
    Kikuchi, Toshiaki
    THORACIC CANCER, 2019, 10 (11) : 2106 - 2116
  • [50] Dacomitinib Versus Gefitinib for First-Line Treatment of Advanced EGFR plus NSCLC in Japanese Patients (ARCHER 1050)
    Nakagawa, K.
    Ohyanagi, F.
    Kato, T.
    Takahashi, T.
    Kaneda, H.
    Nogami, N.
    Niho, S.
    Yamamoto, N.
    Fujita, Y.
    Zhang, H.
    Sbar, E.
    Wang, H.
    Linke, R.
    Tsuji, F.
    Mok, T.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2229 - S2230
12345